-transparent.png){kind=logo}
The vasodilating potency of alpha-human atrial natriuretic peptide (alpha-hANP) was investigated in the forearms of 16 normotensive subjects, 22 to 48 (mean 28) years old, with the use of venous occlusion plethysmography. alpha-hANP, 0.005 to 1.5 micrograms/min/100 ml forearm volume (FAV), infused in nine dose steps into the brachial artery increased forearm blood flow (FAF; ml/min/100 ml FAV) from 2.8 +/- 0.4 (SEM) to a maximum of 9.6 +/- 1.1. Forearm vascular resistance (mean arterial pressure/FAF) decreased by 72%. The alpha-hANP dose that produced a 50% vasodilator response was 0.093 +/- 0.016 microgram/min/100 ml FAV (n = 11) and it resulted in a venous plasma concentration of ANP (pANP) of 115 +/- 7 pmol/liter (normal 2 to 80; radioreceptor assay). Intraindividually, the maximum dose of alpha-hANP induced an increase in FAF that was 60% of the maximum response to sodium nitroprusside (14.1 +/- 1.8). Combined infusions (n = 9) of maximum forearm vasodilator doses of alpha-hANP and nitroprusside increased FAF to 22.7 +/- 3.4; this additive vasodilator effect of alpha-hANP and nitroprusside is consistent with their different actions on the guanylate cyclase system. In man, the direct vasorelaxant effect of alpha-hANP occurs at concentrations within the upper normal range of pANP, suggesting a physiologic vasodilator role for alpha-hANP.
P Bolli, and
F B Müller, and
L Linder, and
A E Raine, and
T J Resink, and
P Erne, and
W Kiowski, and
R Ritz, and
F R Bühler
January 1989,
Journal of steroid biochemistry,
P Bolli, and
F B Müller, and
L Linder, and
A E Raine, and
T J Resink, and
P Erne, and
W Kiowski, and
R Ritz, and
F R Bühler
January 1988,
American journal of nephrology,
P Bolli, and
F B Müller, and
L Linder, and
A E Raine, and
T J Resink, and
P Erne, and
W Kiowski, and
R Ritz, and
F R Bühler
October 1991,
American journal of obstetrics and gynecology,
P Bolli, and
F B Müller, and
L Linder, and
A E Raine, and
T J Resink, and
P Erne, and
W Kiowski, and
R Ritz, and
F R Bühler
July 2003,
European journal of clinical investigation,
P Bolli, and
F B Müller, and
L Linder, and
A E Raine, and
T J Resink, and
P Erne, and
W Kiowski, and
R Ritz, and
F R Bühler
August 1986,
Clinical science (London, England : 1979),
P Bolli, and
F B Müller, and
L Linder, and
A E Raine, and
T J Resink, and
P Erne, and
W Kiowski, and
R Ritz, and
F R Bühler
January 1995,
Journal of the Society for Gynecologic Investigation,
P Bolli, and
F B Müller, and
L Linder, and
A E Raine, and
T J Resink, and
P Erne, and
W Kiowski, and
R Ritz, and
F R Bühler
February 1987,
Life sciences,
P Bolli, and
F B Müller, and
L Linder, and
A E Raine, and
T J Resink, and
P Erne, and
W Kiowski, and
R Ritz, and
F R Bühler
January 2012,
PloS one,
P Bolli, and
F B Müller, and
L Linder, and
A E Raine, and
T J Resink, and
P Erne, and
W Kiowski, and
R Ritz, and
F R Bühler
October 1989,
British journal of clinical pharmacology,
P Bolli, and
F B Müller, and
L Linder, and
A E Raine, and
T J Resink, and
P Erne, and
W Kiowski, and
R Ritz, and
F R Bühler
July 1987,
British heart journal,
